ASH: Rituximab Leads Way in Older Mantle Cell PatientsMedPage TodayAn induction regimen based on rituximab (Rituxan), followed by rituximab maintenance, now appears to be the best treatment choice for older patients with mantle cell lymphoma. Among tho…
ASH: Two Immunochemotherapy Regimens With Rituximab for Newly Diagnosed …Cancer NetworkThe 554 patients enrolled had bulky FL—stage II and higher, and had not received any prior treatment—and were randomized to either the CHOP-R arm, CHOP chemoth…
Less Is More for Rituximab in Low-Burden Follicular LymphomaMedscapeDecember 14, 2011 — For patients with low-tumor-burden follicular lymphoma, new data suggest that treatment with rituximab (Rituxan, Genentech) is better than a "watch-and-wait&…
Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses … – CNBCSan Francisco Luxury NewsThe combination of REVLIMID (lenalidomide) and rituximab, also referred to as the R-squared (or R(2)) regimen pioneered by Nathan Fowler, MD and col…
Novel monoclonal antibody targets CD20 in relapsed NHLHemOncTodaySAN DIEGO — The novel anti-CD20 monoclonal antibody obinutuzumab was linked to better response rates than rituximab in a cohort of patients with relapsed non-Hodgkin's lymphoma, acc…
Celgene, GELA Initiate RELEVANCE Phase III Study In Follicular LymphomaRTT NewsThe combination of REVLIMID and rituximab, also referred to as the R-squared or R2 regimen pioneered by Nathan Fowler, MD and colleagues at the MD Anderson Cancer Center, Ho…
Adding rituximab to chemotherapy regimens improves outcomes for AIDS-related …aidsmapThe addition of rituximab to chemotherapy regimens for the treatment of AIDS-related lymphomas improves both overall survival and progression-free survival, German i…
REVLIMID¬Æ Evaluated in Combination with Rituximab as a Potential Treatment …PharmiWeb.com (press release)Celgene International S√†rl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from an investigational study evaluatin…
Idera Pharmaceuticals Presents Data in Preclinical Models of Lymphoma on IMO …MarketWatch (press release)The presentation by Idera scientists, entitled "IMO-4200, a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, ritux…
Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with …Business Wire (press release)In the study, 59 patients received rituximab 375 mg/m 2 intravenously weekly for four weeks in cycle one, and then once every four weeks during cyc…